store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Naluzotan(PRX 00023) 是一种新型高效的 5-HT1A 激动剂,IC50 和 Ki 值分别为约 20 nM 和 5.1 nM。Naluzotan 是一种有效的 hERG K+ 通道阻滞剂,IC50 值为 3800 nM。Naluzotan 具有抗焦虑活性,可用于研究抑郁症。
产品描述 | Naluzotan(PRX 00023) is a novel and potent 5-HT1A agonist with IC50 and Ki values of approximately 20 nM and 5.1 nM, respectively.Naluzotan is a potent hERG K+ channel blocker with an IC50 value of 3800 nM.Naluzotan exhibits anxiolytic activity and can be used to study depression. |
靶点活性 | Cell-based functional assay:20 nM (EC50), 5-HT1A receptor:20 nM, 5-HT1A receptor:5.1 nM (Ki), σ receptor:100 nM (Ki,guinea pig), ERG K+ channel (human):3800 nM |
体外活性 | Naluzotan, with an EC50 of 20 nM, behaves as a full agonist in an in vitro cell-based functional assay. It exhibits significant affinity for the guinea pig sigma receptor (Ki = 100 nM) but does not inhibit cytochrome P450 isoforms (CYP) 1A2, 2C9, 2C19, 2D6, and 3A4[2]. |
体内活性 | In rats, when administered orally, Naluzotan shows 11% oral bioavailability with a serum half-life (t1/2) of 2−3.5 hours, reaching a Cmax level of 24 ± 13 ng/mL (3 mg/kg, oral). Naluzotan exhibits significant brain penetration, with a brain:serum concentration ratio of approximately 0.5 in rats at 1 hour following either intravenous or oral administration, and it achieves a brain concentration approximately equivalent to that of buspirone. In dogs, the pharmacokinetic profile of naluzotan demonstrates 16% oral bioavailability, a serum t1/2 of 1.1 hours when administered orally, and a Cmax level of 174 ± 141 ng/mL (3 mg/kg, oral)[1]. PRX-00023, at doses of 0.01-0.05 mg/kg administered intraperitoneally, significantly reduces ultrasonic vocalization (USV) rates in rats, but none of these doses induce sedation[1]. |
别名 | PRX 00023 |
分子量 | 450.64 |
分子式 | C23H38N4O3S |
CAS No. | 740873-06-7 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Naluzotan 740873-06-7 Angiogenesis GPCR/G Protein JAK/STAT signaling Neuroscience Tyrosine Kinase/Adaptors EGFR 5-HT Receptor PRX 00023 PRX00023 PRX-00023 Inhibitor inhibitor inhibit